Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient
- 26 April 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 56 (7), 1605-1614
- https://doi.org/10.1007/s00125-013-2906-0
Abstract
Alginate-encapsulated human islet cell grafts have not been able to correct diabetes in humans, whereas free grafts have. This study examined in immunodeficient mice whether alginate-encapsulated graft function was inferior to that of free grafts of the same size and composition. Cultured human islet cells were equally distributed over free and alginate-encapsulated grafts before implantation in, respectively, the kidney capsule and the peritoneal cavity of non-obese diabetic mice with severe combined immunodeficiency and alloxan-induced diabetes. Implants were followed for in vivo function and retrieved for analysis of cellular composition (all) and insulin secretory responsiveness (capsules). Free implants with low beta cell purity (19 ± 1%) were non-functional and underwent 90% beta cell loss. At medium purity (50 ± 1%), they were functional at post-transplant week 1, evolving to normoglycaemia (4/8) or to C-peptide negativity (4/8) depending on the degree of beta cell-specific losses. Encapsulated implants immediately and sustainably corrected diabetes, irrespective of beta cell purity (16/16). Most capsules were retrievable as single units, enriched in endocrine cells that exhibited rapid secretory responses to glucose and glucagon. Single capsules with similar properties were also retrieved from a type 1 diabetic recipient at post-transplant month 3. However, the vast majority were clustered and contained debris, explaining the poor rise in plasma C-peptide. In immunodeficient mice, i.p. implanted alginate-encapsulated human islet cells exhibited a better outcome than free implants under the kidney capsule. They did not show primary non-function at low beta cell purity and avoided beta cell-specific losses by rapidly establishing normoglycaemia. Retrieved capsules presented secretory responses to glucose, which was also observed in a type 1 diabetic recipient. Trial registration: ClinicalTrials.gov NCT01379729 Funding: This study was supported by grants from the JDRF (centre grant 4-2005-1327), the Research Foundation Flanders (G.0801.10), the 6th and 7th Framework Program of the European Commission (numbers 512145 and 241883), and the Agency for Innovation by Science and Technology in Flanders (IWT-TBM7 090884).Keywords
This publication has 55 references indexed in Scilit:
- Long-Term Metabolic and Immunological Follow-Up of Nonimmunosuppressed Patients With Type 1 Diabetes Treated With Microencapsulated Islet AllograftsDiabetes Care, 2011
- Islets Transplanted in Immunoisolation Devices: A Review of the Progress and the Challenges that RemainEndocrine Reviews, 2011
- Differences in Baseline Lymphocyte Counts and Autoreactivity Are Associated With Differences in Outcome of Islet Cell Transplantation in Type 1 Diabetic PatientsDiabetes, 2009
- Safety and Viability of Microencapsulated Human Islets Transplanted Into Diabetic HumansDiabetes Care, 2009
- Disproportionate Hyperproinsulinemia, β-Cell Restricted Prohormone Convertase 2 Deficiency, and Cell Cycle Inhibitors Expression by Human Islets Transplanted into Athymic Nude Mice: Insights into Nonimmune-Mediated Mechanisms of Delayed Islet Graft FailureCell Transplantation, 2008
- Successful Allotransplantation of Encapsulated Islets in Pancreatectomized Canines for Diabetic Management Without the Use of ImmunosuppressionTransplantation, 2008
- Human Islet Oxygen Consumption Rate and DNA Measurements Predict Diabetes Reversal in Nude MiceAmerican Journal of Transplantation, 2007
- Correlation between β cell mass and glycemic control in type 1 diabetic recipients of islet cell graftProceedings of the National Academy of Sciences of the United States of America, 2006
- Microencapsulated Pancreatic Islet Allografts Into Nonimmunosuppressed Patients With Type 1 Diabetes: First two casesDiabetes Care, 2006
- TRANSPLANTATION OF ENCAPSULATED ALLOGENEIC ISLETS INTO DIABETIC BB/W RATSTransplantation, 1991